Business Wire

Adtran advances open networking at OIF’s ECOC 2025 demo with FSP 3000 OLS and coherent pluggables

25.9.2025 15:00:00 EEST | Business Wire | Press release

Share

Adtran today announced its role in the OIF’s open, multi-vendor interoperability demo at ECOC 2025 and highlighted its recent participation in the OIF Plugfest, where its 100ZR+ and 400ZRE coherent pluggables were validated across multiple hosts and platforms. On the ECOC show floor, 100Gbit/s, 400Gbit/s and 800Gbit/s signals generated by coherent pluggable optics will be transported over open line systems (OLS) in a disaggregated IPoDWDM environment. This includes a 300km Adtran FSP 3000 OLS multi-span link and Adtran 100ZR+ and 400ZRE coherent pluggable transceivers operating in third-party hosts and over both Adtran and third-party OLS. The live setup demonstrates how operators can scale capacity with simple turn-up and integrated visibility while preserving vendor choice. Together, these activities underscore Adtran’s commitment to openness at both the system and module levels.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922887315/en/

Adtran’s FSP 3000 OLS and coherent pluggables are set to be major talking points at ECOC 2025.

“Open optical networking is most effective when it empowers operators with flexibility and seamless integration,” said Ryan Schmidt, GM of optical transport at Adtran. “With our FSP 3000 open line system at the center of the ECOC demo, we’re showcasing a reliable 300km multi‑span link in a live multi-speed, multi-vendor environment, with simple activation and clear operational insight. This approach enables providers to expand capacity for cloud and AI workloads, reduce day-to-day complexity, improve energy efficiency and avoid vendor lock‑in while choosing the right technology for each role in the network.”

The ECOC showcase combines live demos and lab validation to show maturity in open optical networking. The FSP 3000 OLS delivers 100Gbit/s and 400Gbit/s services while supporting higher data rates up to 1.6Tbit/s. It uses high‑resolution flexgrid and colorless ROADMs with bidirectional inline amplifiers, plus automation and integrated monitoring, including automated span equalization. The OIF demo also features Adtran’s 100ZR+ and 400ZRE coherent pluggables operating over the FSP 3000 OLS in a multi‑vendor setup. The OIF Plugfest, held ahead of ECOC, extended interoperability testing to the module layer, where Adtran’s 100ZR+ and 400ZRE coherent pluggables were paired with diverse hosts and measurement systems. Adtran’s 100ZR+ and 400ZRE offer 0dBm output for strong performance and low power consumption. These activities demonstrate resilience, operational efficiency and vendor choice for operators building networks for AI, cloud and next‑generation services.

“Interoperability at the module level is essential for open, vendor-neutral networks,” commented Ross Saunders, GM of Optical Engines, Adtran. “Our first-time participation in the OIF Plugfest validated the performance of our 100ZR+ and 400ZRE coherent pluggables across multiple vendors and platforms, with results captured in OIF event materials. This complements the live ECOC demo and underscores the growing industry momentum toward open, multi-vendor optical infrastructures, giving operators confidence that ZR optics from different suppliers will work together in real deployments. It helps de-risk rollouts, support flexible sourcing and keep options open as providers scale to keep pace with AI-driven and cloud-native applications.”

Visitors to ECOC 2025 can view the OIF interoperability demo at booth C3425 from September 29 to October 1. Results from the OIF Plugfest will be published in OIF event materials following the show.

OIF at ECOC 2025: Bridging Gaps, Accelerating Innovation Through Industry-Wide Interoperability

Recognized for advancing interoperability, OIF returns to ECOC 2025 with a live, multi-vendor demo featuring 35 member companies. The demonstration spans optical, electrical, energy efficient and management interfaces, including 400ZR, 800ZR, OpenZR+, CEI-448G, CEI-224G, CEI-112G, Co-Packaging, CMIS, EEI and more. Through broad industry collaboration, OIF continues to close technical gaps and enable open, scalable networks. Visit OIF at booth #C3425 or learn more at www.oiforum.com/meetings-events/oif-ecoc-2025.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250922887315/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye